Oligometastatic prostate cancer: is it worth targeting the tip of the iceberg?

Until recently, the only routinely available imaging techniques of prostate cancer were computed tomography (CT) scan ± contrast, magnetic resonance imaging (MRI) and a standard bone scan. The increasing use of modern imaging techniques such as positron emission tomography-computed tomography (PET-CT) with tumour-specific radiotracers [Choline, Fluciclovine or prostate-specific membrane antigen (PSMA) ligand], and, increasingly, whole-body MRI with diffusion-weighted imaging (WB MRI-DWI), means that oligometastases in prostate cancer are commonly discovered before any radical treatment or once the prostate specific antigen (PSA) has risen following radical treatment.